-- Stifel Canada is maintaining its buy rating and $11.00 price target on the shares of Vitalhub (VHI.TO) after the company said this week that Novari Health, a Vitalhub company, had been awarded a multi-year, multi-million dollar contract award with Ontario Health.
Analyst Justin Keywood views the news positively and says the contract advances management's organic growth goals, while Vitalhub's $119-million net cash balance allows it to remain patient in acquiring the right assets.
"We see VHI as a relatively cheap growth stock, though we expect upcoming quarters to demonstrate management's growth targets (12-13% 2026 organic ARR growth, 10% inorganic) and progress toward 30% adj. EBITDA margins as key in and having investors revisit the story."
Price: $8.16, Change: $+0.12, Percent Change: +1.49%